The effects of Abemaciclib on cell cycle and apoptosis regulation in anaplastic thyroid cancer cells

• Published in: Molecular biology reports 2023-05, Vol.50 (5), p.4073-4082
• Main Authors: Abutorabi, Elaheh S., Poursheikhani, Arash, Kashani, Bahareh, Shamsaiegahkani, Sahar, Haghpanah, Vahid, Bashash, Davood, Mousavi, Seied A., Momeny, Majid, Ghaffari, Seyed H.
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; Animal Anatomy; Animal Biochemistry; Annexin V; Antitumor agents; Apoptosis; Biomedical and Life Sciences; Cell Cycle; Cell growth; Cell Line, Tumor; Cell migration; Cell Proliferation; Cyclin-dependent kinase 4; Cyclin-dependent kinases; Cyclins; Flow cytometry; Gentian violet; Histology; Humans; Kinases; Life Sciences; Malignancy; Morphology; Original Article; Phosphatidylinositol 3-Kinases; Therapeutic targets; Thyroid cancer; Thyroid Carcinoma, Anaplastic - drug therapy; Thyroid Carcinoma, Anaplastic - genetics; Thyroid Neoplasms - genetics; Tumors; Wound healing
• ISSN: 0301-4851; 1573-4978
• DOI: 10.1007/s11033-023-08255-1

Background: Anaplastic thyroid cancer (ATC) is an aggressive subtype of thyroid cancer, accounting for 1 to 2% of all cases. Deregulations of cell cycle regulatory genes including cyclins, cyclin-dependent kinases (CDKs), and endogenous inhibitors of CDKs (CKIs) are hallmarks of cancer cells and hence, studies indicate the inhibition of CDK4/6 kinases and cell cycle progression as potent therapeutic strategies. In this study, we investigated the anti-tumor activity of Abemaciclib, a CDK4 and CDK6 inhibitor, in ATC cell lines. Methods and results: The ATC cell lines C643 and SW1736 were selected to study the antiproliferative effects of Abemaciclib using a cell proliferation assay and crystal violet staining assay. Annexin V/PI staining and cell cycle analysis by flow cytometry were also performed to examine the effects on apoptosis induction and cell cycle arrest. Wound healing assay and zymography analysis examined the effects of the drug on invasive abilities of ATC cells and Western blot analyses were applied to further study the anti-tumor mechanism of Abemaciclib, in addition to combination treatment with alpelisib. Our data demonstrated that Abemaciclib significantly inhibited cell proliferation and increased cellular apoptosis and cell cycle arrest in ATC cell lines, while considerably reducing cell migration and colony formation. The mechanism seemed to involve the PI3K pathway. Conclusion: Our preclinical data highlight CDK4/6 as interesting therapeutic targets in ATC and suggest CDK4/6-blockade therapies as promising strategies in this malignancy.